<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321098</url>
  </required_header>
  <id_info>
    <org_study_id>RD.03.SPR29106</org_study_id>
    <secondary_id>2013-000544-26</secondary_id>
    <nct_id>NCT02321098</nct_id>
  </id_info>
  <brief_title>Antifungal Activity of Loceryl Nail Lacquer in Combination With a Cosmetic Varnish</brief_title>
  <acronym>COOL</acronym>
  <official_title>Determination of Antifungal Activity of Loceryl Nail Lacquer 5% When Used Concomitantly With a Cosmetic Nail Varnish Compared to a Loceryl Nail Lacquer (NL) 5% Alone in Treatment of Toenail Distal Subungual Onychomycosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to compare efficacy, in terms of antifungal activity of Loceryl Nail
      Lacquer associated with a Cosmetic Varnish and Loceryl Nail Lacquer alone, in the treatment
      of mild to moderate toenail Distal Subungual Onychomycosis.

      The second objective of this study will be photographic follow-up of clinical improvement and
      cure after the initial treatment period of 12 weeks, for 15 additional months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study center:

      A total of 50 subjects were to be included in 1 site in Iceland.

      Methodology:

        -  Group Loceryl Nail Lacquer+ Cosmetic Varnish:

             -  Loceryl Nail Lacquer to be applied once weekly for 12 weeks on all affected
                toenails,

             -  Cosmetic varnish to be applied once weekly for 12 weeks on all affected toenails
                and/or all toenails.

        -  Group Loceryl Nail Lacquer alone:

           - Loceryl Nail Lacquer to be applied once weekly for 12 weeks on all affected toenails.

        -  All eligible subejct with no clinical sign of clinical aggravation of Onychomycosis at
           week 12, could continue to apply Loceryl Nail Lacquer alone, once a week for 15
           additional months (or less in case of complete cure).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Only 12 first weeks of treatment with Loceryl NL and/or Loceryl alone were investigator masked and randomized.
15 months of treatment with Loceryl NL alone had an open study design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Antifungal Activity of Loceryl Nail Lacquer</measure>
    <time_frame>Week 12</time_frame>
    <description>Measurement of diameter of zones of inhibition (mm) produced by residual drug in toenails</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absence of Dermatophytes in Nail Samples Culture</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Foot Dermatoses</condition>
  <arm_group>
    <arm_group_label>Investigator blinded Loceryl NL+ Cosmetic varnish</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loceryl NL+ Cosmetic varnish once/week for 12 weeks on right or left foot toenails</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Investigator blinded Loceryl NL alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Loceryl NL once/week for 12 weeks on right or left foot toenails</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loceryl NL + Cosmetic varnish</intervention_name>
    <description>Loceryl NL + Cosmetic varnish once/week for 12 weeks</description>
    <arm_group_label>Investigator blinded Loceryl NL+ Cosmetic varnish</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loceryl NL 12 weeks</intervention_name>
    <description>Loceryl NL once/week for 12 weeks</description>
    <arm_group_label>Investigator blinded Loceryl NL alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loceryl NL 15 months</intervention_name>
    <description>Loceryl once/week for additional 15 months</description>
    <arm_group_label>Investigator blinded Loceryl NL alone</arm_group_label>
    <arm_group_label>Investigator blinded Loceryl NL+ Cosmetic varnish</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with a mild to moderate Distal Subungual Onychomycosis (DSO) on at least 1
             great toenail chosen as a Target nail

          -  Subjects must have maximum of 50% of nail distal edge involved

          -  Subjects with positive mycological results (direct microscopy and culture) of the
             Target nail for dermatophytes or Yeast (including Candida) at Screening

        Exclusion Criteria:

          -  Subjects with clinically important abnormal physical findings at the
             Screening/Baseline visit

          -  Subjects with Lichen planus, eczema, psoriasis, or other abnormalities of the nail
             unit

          -  Subjects with known immunodeficiencies, radiation therapy, immune suppressive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Principal Investigator</name>
      <address>
        <city>Reykjavik</city>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iceland</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>December 8, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <results_first_submitted>March 2, 2018</results_first_submitted>
  <results_first_submitted_qc>March 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 9, 2018</results_first_posted>
  <last_update_submitted>March 2, 2018</last_update_submitted>
  <last_update_submitted_qc>March 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Onychomycosis</keyword>
  <keyword>antifungal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Skin Diseases</mesh_term>
    <mesh_term>Foot Dermatoses</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amorolfine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>50 subjects included to treat their affected toenails with Loceryl NL with or without Cosmetic Varnish for 12 weeks, First Subject In (FSI) = 11 Feb 2014, Last Subject Out (LSO) = 31 Oct 2014
29 subjects without aggravation of their disease treated their toenails with Loceryl NL 15 additional months: FSI = 03 Nov 2014, LSO = 21Jan 2016</recruitment_details>
      <pre_assignment_details>At screening all subjects had a mycological sampling of one of the diseased great toenails. Only screened subjects with both positive mycological results (direct microscopy and culture) at Baseline are randomized into one of the two arms for 12 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Loceryl NL+ Cosmetic Varnish</title>
          <description>Loceryl NL + Cosmetic varnish once/week for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Loceryl NL 12 Weeks</title>
          <description>Loceryl NL once/week for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Loceryl NL 15 Months</title>
          <description>Loceryl NL once/week for additional 15 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>12 Weeks Treament</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Additional 15 Months Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ITT population</population>
      <group_list>
        <group group_id="B1">
          <title>Loceryl NL+Cosmetic Varnish</title>
          <description>Loceryl NL+Cosmetic varnish once/week for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Loceryl NL 12 Weeks</title>
          <description>Loceryl NL once/week for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Loceryl NL15 Months</title>
          <description>Loceryl NL once/week for 15 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>In Loceryl + cosmetic varnish arm 14 subjects out of 25 and 15 subjects out of 23 in Loceryl alone arm having completed 12 weeks Treatment period, continued to apply Loceryl for additional 15 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Treatment period</title>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>Treatment period: 50 subjects are included in two arms for 12 weeks</description>
          <population>From the 50 included subjects, 48 completed the study treatment period of 12 weeks and only 29 were eligible to continue to apply 15 additional months Loceryl NL</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Treatment Period</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="12.0"/>
                    <measurement group_id="B2" value="53.7" spread="12.5"/>
                    <measurement group_id="B4" value="54.4" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Not all subjects randomized in treatment period (50) were eligible to apply Loceryl NL 15 additional months (29 subjects only were eligible)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Treatment Period</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <population>In Loceryl + cosmetic varnish arm 14 subjects out of 25 and 15 subjects out of 23 in Loceryl alone arm having completed 12 weeks Treatment period, continued to apply Loceryl for additional 15 months</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Iceland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B4" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Antifungal Activity of Loceryl Nail Lacquer</title>
        <description>Measurement of diameter of zones of inhibition (mm) produced by residual drug in toenails</description>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loceryl NL+Cosmetic Varnish</title>
            <description>Loceryl NL+Cosmetic varnish once/week for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Loceryl NL 12 Weeks</title>
            <description>Loceryl NL once/week for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Antifungal Activity of Loceryl Nail Lacquer</title>
          <description>Measurement of diameter of zones of inhibition (mm) produced by residual drug in toenails</description>
          <units>Milimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" spread="9.1"/>
                    <measurement group_id="O2" value="53.5" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absence of Dermatophytes in Nail Samples Culture</title>
        <time_frame>Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Loceryl NL+ Cosmetic Varnish + Loceryl NL</title>
            <description>Once weekly application of Loceryl NL + Cosmetic varnish during 12 weeks followed by Loceryl NL once weekly applications for 15 additional months</description>
          </group>
          <group group_id="O2">
            <title>Loceryl NL + Loceryl NL</title>
            <description>Once weekly application of Loceryl NL alone during 12 weeks followed by Loceryl NL once weekly applications for 15 additional months</description>
          </group>
        </group_list>
        <measure>
          <title>Absence of Dermatophytes in Nail Samples Culture</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events are collected during both study periods (Treatment period of 12 weeks and additional period of 15 months treatment)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Loceryl NL+Cosmetic Varnish</title>
          <description>Loceryl NL+Cosmetic varnish once/week for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Loceryl NL 12 Weeks</title>
          <description>Loceryl NL alone once/week for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Loceryl NL 15 Months</title>
          <description>Loceryl NL once/week for additional 15 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CARCINOMA SQUAMOCELLULARE IN LEFT TONSILLARY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>TONSILLITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Farzaneh Sidou Clinical Project Manager</name_or_title>
      <organization>Galderma</organization>
      <phone>04 93 95 70 51 ext 33</phone>
      <email>farzaneh.sidou@galderma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

